Celyad Sa Ads (CYAD) 21.09 $CYAD
CELYAD S.A.: Celyad CEO to present at the 2016 Cell & Gene Meeting on the Mesa
GlobeNewswire - Thu Sep 15, 12:06AM CDT
Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, today announced that Dr. Christian Homsy, Chief Executive Officer, will present and participate in a panel discussion at the upcoming Gene and Cell Therapy Meeting on the Mesa being held October 5-7, 2016 in La Jolla, CA, USA.
CYAD: 21.09 (+0.31)
CELYAD S.A.: Celyad completes the NKR-2 Phase I trial with successful safety follow-up of the fourth dose level
GlobeNewswire - Fri Sep 09, 12:10AM CDT
Celyad completes the NKR-2 Phase I trial with successful safety follow-up of the fourth dose level
CYAD: 21.09 (+0.31)
Celyad Reports First Half 2016 Financial Results and Operational Progress
GlobeNewswire - Thu Aug 25, 12:09AM CDT
Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of cell therapies, today announced its consolidated financial results for the six-month period ending 30 June 2016 prepared in accordance with IFRS as endorsed by the European Union. The full interim financial report (regulated information) is available on our website in the Investors section. The Half Year 2016 consolidated financial statements were subject to a limited review by the company's statutory auditors.
CYAD: 21.09 (+0.31)
Edison Issues ADR Update on Celyad
PR Newswire - Fri Jun 10, 6:33AM CDT
Celyad can now move to the highest planned dose of 3x107 cells in the important NKR-2 Phase II CAR trial. If the next 30m cell dose is also safe (and the MTD) it will lead to two separate six patient open label studies in Acute Myeloid Leukemia and Multiple Myeloma. Further data is possible in late June. Efficacy indications in either of these could enable a series of solid tumor exploratory studies. The advantage of the NKR-T immuno-oncology approach is that it is easily transferred to multiple cancer types. FY15 accounts were as expected with year-end cash of $122m.
CYAD: 21.09 (+0.31)
Colon Cancer Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/pbmf4p/colon_cancer) has announced the addition of the "Colon Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Colon Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colon Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Colon Cancer Overview - Therapeutics Development - Pipeline Products for Colon Cancer - Overview - Pipeline Products for Colon Cancer - Comparative Analysis - Colon Cancer - Therapeutics under Development by Companies - Colon Cancer - Therapeutics under Investigation by Universities/Institutes - Colon Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Colon Cancer - Products under Development by Companies - Colon Cancer - Products under Investigation by Universities/Institutes - Colon Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - ACF Pharmaceuticals, LLC - Aduro BioTech, Inc. - Advanced Proteome Therapeutics Corporation - Advenchen Laboratories, LLC - Agenus, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alethia Biotherapeutics Inc. - Ambrx, Inc. - Anavex Life Sciences Corp. - AndroScience Corporation - ANP Technologies, Inc. - Aphios Corporation - Aposense Ltd. - Aptose Biosciences Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bio-Path Holdings, Inc. - Biogazelle - Bioncotech Therapeutics S.L. - Caladrius Biosciences, Inc. - Can-Fite BioPharma Ltd. - Carna Biosciences, Inc. - Celyad SA - Critical Outcome Technologies Inc. - CureFAKtor Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/pb...lon_cancer
ADRO: 14.54 (-0.25), AMBX: (), CLBS: 4.88 (+0.25), CANF: 2.63 (-0.05), APTO: 2.15 (unch), AVXL: 3.11 (-0.17), BPTH: 1.39 (-0.05), AZN: 33.97 (-0.31), CYAD: 21.09 (+0.31)
Invetech and Celyad SA Announce Collaboration to Realize the Commercial cGMP Production of C-Cure®
PR Newswire Europe - Wed Feb 03, 12:00AM CST
Invetech to design and supply automated production systems for commercialization of autologous cell therapy based on Celyad's cardiopoiesis technology platform
CYAD: 21.09 (+0.31)
Celyad Appoints Dr. Richard Mountfield as Vice-President of Global Regulatory Affairs
GlobeNewswire - Wed Feb 03, 12:00AM CST
Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today announced the appointment of Dr. Richard Mountfield as Vice-President of Global Regulatory Affairs, effective February 3 , 2016.
NVO: 44.88 (-0.69), CYAD: 21.09 (+0.31), NVS: 81.48 (-0.55)
Celyad Announces 2016 Financial Calendar
GlobeNewswire - Wed Jan 20, 12:00AM CST
Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today announced 2016 Financial Calendar.
CYAD: 21.09 (+0.31)
Chronic Heart Failure - Pipeline Review 2015
M2 - Thu Jan 14, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/4rlh37/chronic_heart) has announced the addition of the "Chronic Heart Failure - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Chronic Heart Failure Overview - Therapeutics Development - Pipeline Products for Chronic Heart Failure - Overview - Pipeline Products for Chronic Heart Failure - Comparative Analysis - Chronic Heart Failure - Therapeutics under Development by Companies - Chronic Heart Failure - Therapeutics under Investigation by Universities/Institutes - Chronic Heart Failure - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Chronic Heart Failure - Products under Development by Companies - Chronic Heart Failure - Products under Investigation by Universities/Institutes - Chronic Heart Failure - Companies Involved in Therapeutics Development - Amgen Inc. - AnGes MG, Inc. - ARCA biopharma, Inc. - Bayer AG - Bial - Portela & Ca, S.A. - Caladrius Biosciences, Inc. - Capricor Therapeutics, Inc. - Celyad SA - Jiangsu Hengrui Medicine Co., Ltd. - Juventas Therapeutics, Inc. - Laboratoires Pierre Fabre SA - Les Laboratoires Servier SAS - Mast Therapeutics, Inc. - Mesoblast Limited - Novartis AG - Pfizer Inc. - PhaseBio Pharmaceuticals, Inc. - Sanofi - Stemedica Cell Technologies, Inc. - Vichem Chemie Research Ltd. - Zensun (Shanghai) Sci & Tech Co., Ltd. For more information visit http://www.researchandmarkets.com/research/4r...onic_heart
CAPR: 3.51 (-0.12), MESO: 4.42 (-0.17), MSTX: 0.13 (unch), PFE: 34.26 (+0.11), AMGN: 174.80 (-0.82), CLBS: 4.88 (+0.25), NVS: 81.48 (-0.55), CYAD: 21.09 (+0.31)
Celyad Completes 30-Day Safety Follow-Up of First Patient of Second Cohort in NKG2D CAR T-Cell Phase I Trial
GlobeNewswire - Tue Jan 05, 12:00AM CST
-- No dose limiting toxicity related to the investigational treatment reported at 30 days post treatment of the first patient of the second dose-level;
CYAD: 21.09 (+0.31)
Celyad's C-Cure IND Authorized in U.S. for Phase III Study
Zacks Equity Research - Zacks Investment Research - Wed Dec 23, 3:10PM CST
Celyad's (CYAD) IND application to proceed C-Cure to a phase III study has been authorized in the U.S.
ACHN: 8.69 (+0.25), ANIK: 46.92 (-1.07), CORT: 6.49 (unch), CYAD: 21.09 (+0.31)
Celyad to Address US Institutional Investors in January at J.P. Morgan Healthcare Conference
GlobeNewswire - Wed Dec 23, 12:00AM CST
Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today announced its participation to the 34 edition of the annual J.P. Morgan Healthcare Conference which will be held from 11 to 15 January 2016 in San Francisco.
JPM: 67.25 (-0.14), CYAD: 21.09 (+0.31)
Celyad Receives Clearance From the US FDA on Its CHART-2 Phase III IND
GlobeNewswire - Mon Dec 21, 12:00AM CST
Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today announced that the U.S. Food and Drug Administration (FDA) has authorized the Company's Investigational New Drug (IND) application to proceed thus allowing for the clinical testing of Celyad's lead cardiology candidate (C-Cure cardiopoietic cells) delivered via the proprietary catheter (C-Cathez) in the Phase III Heart Failure Trial (CHART-2) in the US.
CYAD: 21.09 (+0.31)
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
BusinessWire - Wed Dec 16, 6:00AM CST
Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy Index, a group of the top 30 companies developing cancer immunotherapy treatments and finding new ways to use the body's immune system to fight cancer.
NWBO: 0.53 (-0.02), TSRO: 108.59 (+0.16), CTMX: 15.64 (-1.02), NK: 7.91 (-0.32), CNCR: 26.09 (-0.09), SRNE: 7.77 (-0.10), XNCR: 25.06 (-0.11), ONTY: 1.21 (+0.02), CYAD: 21.09 (+0.31)
Celyad Announces the Publication of Its CHART-1 Trial Design Methods Paper in the European Journal of Heart Failure
GlobeNewswire - Wed Dec 16, 12:00AM CST
Celyad (Euronext Brussels and Paris, and NASDAQ:CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today announces that a methods paper on the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) clinical trial design has been published in the European Journal of Heart Failure (EJHF 2015).
CYAD: 21.09 (+0.31)
Myocardial Infarction Therapeutics Pipeline Review, H2 2015
M2 - Fri Dec 11, 6:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/dvg76b/myocardial) has announced the addition of the "Myocardial Infarction - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myocardial Infarction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Infarction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alligator Bioscience AB - Amarantus Bioscience Holdings, Inc. - Angion Biomedica Corp. - Aprogen, Inc. - APT Therapeutics, Inc. - AstraZeneca Plc - Athersys, Inc. - Bayer AG - Bharat Biotech International Limited - BioLineRx, Ltd. - Biscayne Pharmaceuticals, Inc. - CellProthera - Celyad - Fina Biotech - Hadasit Medical Research Services & Development Ltd - Human Stem Cells Institute - HUYA Bioscience International, LLC - Immune Pharmaceuticals Inc. - Inbiopro Solutions Pvt. Ltd. - Juventas Therapeutics, Inc. - Laboratoires Pierre Fabre SA - Lacer, S.A. - miRagen Therapeutics, Inc. - NeuroVive Pharmaceutical AB - Omeros Corporation - Recardio GmbH - Remedy Pharmaceuticals, Inc. - Serodus ASA - STELIS Biopharma Pvt. Ltd. - Stemedica Cell Technologies, Inc. - Stempeutics Research Private Limited - TaiGen Biotechnology Co., Ltd. - Yuyu Pharma, Inc. - Zealand Pharma A/S - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/dvg76b/myocardial
AZN: 33.97 (-0.31), IMNP: 0.28 (unch), ATHX: 2.02 (+0.02), OMER: 11.64 (-0.26), CYAD: 21.09 (+0.31)
Celyad Starts 2nd Cohort of Phase I on NKG2D CAR T-Cell
Zacks Equity Research - Zacks Investment Research - Wed Dec 02, 3:55PM CST
Celyad (CYAD) announced that it has treated the first patient in the second cohort of its phase I study on NKG2D CAR T-Cell for the treatment of patients with AML and MM.
ACHN: 8.69 (+0.25), PFE: 34.26 (+0.11), CORT: 6.49 (unch), CYAD: 21.09 (+0.31)
Celyad Treats First Patient of Second Cohort in NKG2D CAR T-Cell Phase I Trial
GlobeNewswire - Tue Dec 01, 12:00AM CST
Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today announced the infusion of the first patient of the second cohort of its Phase I clinical trial evaluating the Company's NKG2D CAR T-Cell therapy in acute myeloid leukaemia (AML) and multiple myeloma (MM) indications.
CYAD: 21.09 (+0.31)
Celyad Successfully Completes 30-Day Safety Follow-Up of First Patient Cohort in NKG2D CAR T-Cell Phase I Trial
GlobeNewswire - Tue Nov 10, 12:00AM CST
-- No treatment-related safety issues reported at 30 days post-treatment of all patients in first cohort of the trial following single dose NKG2D CAR T-Cell infusion
CYAD: 21.09 (+0.31)
CELYAD S.A.: Celyad CEO to present at the 2016 Cell & Gene Meeting on the Mesa
GlobeNewswire - Thu Sep 15, 12:06AM CDT
Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, today announced that Dr. Christian Homsy, Chief Executive Officer, will present and participate in a panel discussion at the upcoming Gene and Cell Therapy Meeting on the Mesa being held October 5-7, 2016 in La Jolla, CA, USA.
CYAD: 21.09 (+0.31)
CELYAD S.A.: Celyad completes the NKR-2 Phase I trial with successful safety follow-up of the fourth dose level
GlobeNewswire - Fri Sep 09, 12:10AM CDT
Celyad completes the NKR-2 Phase I trial with successful safety follow-up of the fourth dose level
CYAD: 21.09 (+0.31)
Celyad Reports First Half 2016 Financial Results and Operational Progress
GlobeNewswire - Thu Aug 25, 12:09AM CDT
Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of cell therapies, today announced its consolidated financial results for the six-month period ending 30 June 2016 prepared in accordance with IFRS as endorsed by the European Union. The full interim financial report (regulated information) is available on our website in the Investors section. The Half Year 2016 consolidated financial statements were subject to a limited review by the company's statutory auditors.
CYAD: 21.09 (+0.31)
Edison Issues ADR Update on Celyad
PR Newswire - Fri Jun 10, 6:33AM CDT
Celyad can now move to the highest planned dose of 3x107 cells in the important NKR-2 Phase II CAR trial. If the next 30m cell dose is also safe (and the MTD) it will lead to two separate six patient open label studies in Acute Myeloid Leukemia and Multiple Myeloma. Further data is possible in late June. Efficacy indications in either of these could enable a series of solid tumor exploratory studies. The advantage of the NKR-T immuno-oncology approach is that it is easily transferred to multiple cancer types. FY15 accounts were as expected with year-end cash of $122m.
CYAD: 21.09 (+0.31)
Colon Cancer Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/pbmf4p/colon_cancer) has announced the addition of the "Colon Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Colon Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colon Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Colon Cancer Overview - Therapeutics Development - Pipeline Products for Colon Cancer - Overview - Pipeline Products for Colon Cancer - Comparative Analysis - Colon Cancer - Therapeutics under Development by Companies - Colon Cancer - Therapeutics under Investigation by Universities/Institutes - Colon Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Colon Cancer - Products under Development by Companies - Colon Cancer - Products under Investigation by Universities/Institutes - Colon Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - ACF Pharmaceuticals, LLC - Aduro BioTech, Inc. - Advanced Proteome Therapeutics Corporation - Advenchen Laboratories, LLC - Agenus, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alethia Biotherapeutics Inc. - Ambrx, Inc. - Anavex Life Sciences Corp. - AndroScience Corporation - ANP Technologies, Inc. - Aphios Corporation - Aposense Ltd. - Aptose Biosciences Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bio-Path Holdings, Inc. - Biogazelle - Bioncotech Therapeutics S.L. - Caladrius Biosciences, Inc. - Can-Fite BioPharma Ltd. - Carna Biosciences, Inc. - Celyad SA - Critical Outcome Technologies Inc. - CureFAKtor Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/pb...lon_cancer
ADRO: 14.54 (-0.25), AMBX: (), CLBS: 4.88 (+0.25), CANF: 2.63 (-0.05), APTO: 2.15 (unch), AVXL: 3.11 (-0.17), BPTH: 1.39 (-0.05), AZN: 33.97 (-0.31), CYAD: 21.09 (+0.31)
Invetech and Celyad SA Announce Collaboration to Realize the Commercial cGMP Production of C-Cure®
PR Newswire Europe - Wed Feb 03, 12:00AM CST
Invetech to design and supply automated production systems for commercialization of autologous cell therapy based on Celyad's cardiopoiesis technology platform
CYAD: 21.09 (+0.31)
Celyad Appoints Dr. Richard Mountfield as Vice-President of Global Regulatory Affairs
GlobeNewswire - Wed Feb 03, 12:00AM CST
Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today announced the appointment of Dr. Richard Mountfield as Vice-President of Global Regulatory Affairs, effective February 3 , 2016.
NVO: 44.88 (-0.69), CYAD: 21.09 (+0.31), NVS: 81.48 (-0.55)
Celyad Announces 2016 Financial Calendar
GlobeNewswire - Wed Jan 20, 12:00AM CST
Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today announced 2016 Financial Calendar.
CYAD: 21.09 (+0.31)
Chronic Heart Failure - Pipeline Review 2015
M2 - Thu Jan 14, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/4rlh37/chronic_heart) has announced the addition of the "Chronic Heart Failure - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Chronic Heart Failure Overview - Therapeutics Development - Pipeline Products for Chronic Heart Failure - Overview - Pipeline Products for Chronic Heart Failure - Comparative Analysis - Chronic Heart Failure - Therapeutics under Development by Companies - Chronic Heart Failure - Therapeutics under Investigation by Universities/Institutes - Chronic Heart Failure - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Chronic Heart Failure - Products under Development by Companies - Chronic Heart Failure - Products under Investigation by Universities/Institutes - Chronic Heart Failure - Companies Involved in Therapeutics Development - Amgen Inc. - AnGes MG, Inc. - ARCA biopharma, Inc. - Bayer AG - Bial - Portela & Ca, S.A. - Caladrius Biosciences, Inc. - Capricor Therapeutics, Inc. - Celyad SA - Jiangsu Hengrui Medicine Co., Ltd. - Juventas Therapeutics, Inc. - Laboratoires Pierre Fabre SA - Les Laboratoires Servier SAS - Mast Therapeutics, Inc. - Mesoblast Limited - Novartis AG - Pfizer Inc. - PhaseBio Pharmaceuticals, Inc. - Sanofi - Stemedica Cell Technologies, Inc. - Vichem Chemie Research Ltd. - Zensun (Shanghai) Sci & Tech Co., Ltd. For more information visit http://www.researchandmarkets.com/research/4r...onic_heart
CAPR: 3.51 (-0.12), MESO: 4.42 (-0.17), MSTX: 0.13 (unch), PFE: 34.26 (+0.11), AMGN: 174.80 (-0.82), CLBS: 4.88 (+0.25), NVS: 81.48 (-0.55), CYAD: 21.09 (+0.31)
Celyad Completes 30-Day Safety Follow-Up of First Patient of Second Cohort in NKG2D CAR T-Cell Phase I Trial
GlobeNewswire - Tue Jan 05, 12:00AM CST
-- No dose limiting toxicity related to the investigational treatment reported at 30 days post treatment of the first patient of the second dose-level;
CYAD: 21.09 (+0.31)
Celyad's C-Cure IND Authorized in U.S. for Phase III Study
Zacks Equity Research - Zacks Investment Research - Wed Dec 23, 3:10PM CST
Celyad's (CYAD) IND application to proceed C-Cure to a phase III study has been authorized in the U.S.
ACHN: 8.69 (+0.25), ANIK: 46.92 (-1.07), CORT: 6.49 (unch), CYAD: 21.09 (+0.31)
Celyad to Address US Institutional Investors in January at J.P. Morgan Healthcare Conference
GlobeNewswire - Wed Dec 23, 12:00AM CST
Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today announced its participation to the 34 edition of the annual J.P. Morgan Healthcare Conference which will be held from 11 to 15 January 2016 in San Francisco.
JPM: 67.25 (-0.14), CYAD: 21.09 (+0.31)
Celyad Receives Clearance From the US FDA on Its CHART-2 Phase III IND
GlobeNewswire - Mon Dec 21, 12:00AM CST
Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today announced that the U.S. Food and Drug Administration (FDA) has authorized the Company's Investigational New Drug (IND) application to proceed thus allowing for the clinical testing of Celyad's lead cardiology candidate (C-Cure cardiopoietic cells) delivered via the proprietary catheter (C-Cathez) in the Phase III Heart Failure Trial (CHART-2) in the US.
CYAD: 21.09 (+0.31)
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
BusinessWire - Wed Dec 16, 6:00AM CST
Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy Index, a group of the top 30 companies developing cancer immunotherapy treatments and finding new ways to use the body's immune system to fight cancer.
NWBO: 0.53 (-0.02), TSRO: 108.59 (+0.16), CTMX: 15.64 (-1.02), NK: 7.91 (-0.32), CNCR: 26.09 (-0.09), SRNE: 7.77 (-0.10), XNCR: 25.06 (-0.11), ONTY: 1.21 (+0.02), CYAD: 21.09 (+0.31)
Celyad Announces the Publication of Its CHART-1 Trial Design Methods Paper in the European Journal of Heart Failure
GlobeNewswire - Wed Dec 16, 12:00AM CST
Celyad (Euronext Brussels and Paris, and NASDAQ:CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today announces that a methods paper on the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) clinical trial design has been published in the European Journal of Heart Failure (EJHF 2015).
CYAD: 21.09 (+0.31)
Myocardial Infarction Therapeutics Pipeline Review, H2 2015
M2 - Fri Dec 11, 6:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/dvg76b/myocardial) has announced the addition of the "Myocardial Infarction - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myocardial Infarction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Infarction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alligator Bioscience AB - Amarantus Bioscience Holdings, Inc. - Angion Biomedica Corp. - Aprogen, Inc. - APT Therapeutics, Inc. - AstraZeneca Plc - Athersys, Inc. - Bayer AG - Bharat Biotech International Limited - BioLineRx, Ltd. - Biscayne Pharmaceuticals, Inc. - CellProthera - Celyad - Fina Biotech - Hadasit Medical Research Services & Development Ltd - Human Stem Cells Institute - HUYA Bioscience International, LLC - Immune Pharmaceuticals Inc. - Inbiopro Solutions Pvt. Ltd. - Juventas Therapeutics, Inc. - Laboratoires Pierre Fabre SA - Lacer, S.A. - miRagen Therapeutics, Inc. - NeuroVive Pharmaceutical AB - Omeros Corporation - Recardio GmbH - Remedy Pharmaceuticals, Inc. - Serodus ASA - STELIS Biopharma Pvt. Ltd. - Stemedica Cell Technologies, Inc. - Stempeutics Research Private Limited - TaiGen Biotechnology Co., Ltd. - Yuyu Pharma, Inc. - Zealand Pharma A/S - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/dvg76b/myocardial
AZN: 33.97 (-0.31), IMNP: 0.28 (unch), ATHX: 2.02 (+0.02), OMER: 11.64 (-0.26), CYAD: 21.09 (+0.31)
Celyad Starts 2nd Cohort of Phase I on NKG2D CAR T-Cell
Zacks Equity Research - Zacks Investment Research - Wed Dec 02, 3:55PM CST
Celyad (CYAD) announced that it has treated the first patient in the second cohort of its phase I study on NKG2D CAR T-Cell for the treatment of patients with AML and MM.
ACHN: 8.69 (+0.25), PFE: 34.26 (+0.11), CORT: 6.49 (unch), CYAD: 21.09 (+0.31)
Celyad Treats First Patient of Second Cohort in NKG2D CAR T-Cell Phase I Trial
GlobeNewswire - Tue Dec 01, 12:00AM CST
Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today announced the infusion of the first patient of the second cohort of its Phase I clinical trial evaluating the Company's NKG2D CAR T-Cell therapy in acute myeloid leukaemia (AML) and multiple myeloma (MM) indications.
CYAD: 21.09 (+0.31)
Celyad Successfully Completes 30-Day Safety Follow-Up of First Patient Cohort in NKG2D CAR T-Cell Phase I Trial
GlobeNewswire - Tue Nov 10, 12:00AM CST
-- No treatment-related safety issues reported at 30 days post-treatment of all patients in first cohort of the trial following single dose NKG2D CAR T-Cell infusion
CYAD: 21.09 (+0.31)
